Holen Sie sich die Stockscreener-App
487.61
0.54%
-2.63
Handel nachbörslich:
487.61
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$490.24
Offen:
$484.33
24-Stunden-Volumen:
326.99K
Relative Volume:
0.68
Marktkapitalisierung:
$20.91B
Einnahmen:
$3.17B
Nettoeinkommen (Verlust:
$1.29B
KGV:
18.00
EPS:
27.0947
Netto-Cashflow:
$1.01B
1W Leistung:
-5.40%
1M Leistung:
-5.99%
6M Leistung:
-0.53%
1J Leistung:
+28.16%
1-Tages-Spanne:
$484.33
$494.08
1-Wochen-Bereich:
$477.01
$517.75
52-Wochen-Spanne:
$375.61
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
United Therapeutics (NASDAQ: UTHR) CEO sale part of 1,734,410-option 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) legal chief sells 8,300 shares - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO trades under 1,734,410-option 10b5-1 plan - Stock Titan
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns - ChartMill
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
United Therapeutics (UTHR) CEO sells shares under preset trading plan - Stock Titan
United Therapeutics Corp (UTHR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares - Stock Titan
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript - AOL.com
United Therapeutics Completes Enrollment in Phase 3 PPF Trial of Tyvaso - marketscreener.com
United Therapeutics completes enrollment in lung fibrosis trial - Investing.com
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis - marketscreener.com
United Therapeutics Corporation Completes Enrollment Of TETON-PPF Study Of Inhaled Treprostinil For Progressive Pulmonary Fibrosis - marketscreener.com
United Therapeutics Corporation (UTHR) Stock Analysis: Potential 30% Upside Captivates Investors - DirectorsTalk Interviews
Mid Cap Index Fund's United Therapeutics Corp(UTHR) Holding History - GuruFocus
United Therapeutics CEO Martine Rothblatt sells $4.79m in stock By Investing.com - Investing.com South Africa
United Therapeutics CEO Martine Rothblatt sells $4.79m in stock - Investing.com
United Therapeutics (UTHR) CEO Rothblatt exercises 9,500 options and sells 9,500 shares via 10b5-1 plan - Stock Titan
UTHR|United Therapeutics Corp|Price:499.730|Chg%:-1.540 - TradingKey
United Therapeutics CEO Rothblatt sells $4.89m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $4.89m in stock - Investing.com
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp (UTHR) CEO’s trust sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) Stock Looks Undervalued Despite Fresh NDA Filings - simplywall.st
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play - ChartMill
United Therapeutics Corp (UTHR) CEO trades 9,500 shares after option exercise - Stock Titan
UNITED THERAPEUTICS CORP (UTHR.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
United Therapeutics chairperson & CEO sells $5.05m in stock By Investing.com - Investing.com Australia
United Therapeutics (UTHR) CEO trades 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics chairperson & CEO sells $5.05m in stock - Investing.com
Baylor College of Medicine strikes multimillion-dollar deal with United Therapeutics for transplant center - The Business Journals
United Therapeutics (UTHR) CEO trades 9,500 shares under 10b5-1 option plan - Stock Titan
Assenagon Asset Management S.A. Purchases 37,355 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise - Stock Titan
United Therapeutics (NASDAQ:UTHR) Sees Strong Trading VolumeShould You Buy? - MarketBeat
United Therapeutics EVP & general counsel Mahon sells $4.29m in shares - Investing.com South Africa
United Therapeutics Corporation $UTHR Shares Sold by Bank of America Corp DE - MarketBeat
United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock - MarketBeat
United Therapeutics Balances Tyvaso Woes With Pipeline Wins - The Globe and Mail
United Therapeutics (UTHR) counsel exercises options, sells 8,300 shares - Stock Titan
United Therapeutics Corp (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
Royal Bank Of Canada Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock Price - marketbeat.com
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark - Yahoo Finance
United Therapeutics Corp (UTHR) (Q2 2026) Earnings Call Highligh - GuruFocus
United Therapeutics Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
BofA cuts United Therapeutics stock price target on Tyvaso sales - Investing.com
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
United Therapeutics Corp-Aktie (UTHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Sep 03 '26 |
Sale |
482.03 |
8,300 |
4,000,836 |
45,172 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 02 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 02 '26 |
Sale |
493.46 |
9,500 |
4,687,841 |
324,443 |
0.35%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):